Early effect of pravastatin on serum soluble CD40L, matrix metalloproteinase-9, and C-reactive protein in patients with acute myocardial infarction

Clin Chem. 2004 Sep;50(9):1696-9. doi: 10.1373/clinchem.2003.030940. Epub 2004 Jul 20.

Authors

Jiang Li¹, Shui-Ping Zhao, Dao-quan Peng, Zhu-mei Xu, Hong-nian Zhou

Affiliation

¹ Department of Cardiology, the Second Xiangya Hospital, Central South University, Changsha, Hunan, China.

PMID: 15265816
DOI: 10.1373/clinchem.2003.030940

No abstract available

Publication types

Clinical Trial
Comparative Study
Randomized Controlled Trial

MeSH terms

Anticholesteremic Agents / pharmacology*
Anticholesteremic Agents / therapeutic use
C-Reactive Protein / metabolism
CD40 Ligand / blood
Double-Blind Method
Female
Humans
Male
Matrix Metalloproteinase 9 / blood
Myocardial Infarction / blood*
Myocardial Infarction / drug therapy*
Myocardial Infarction / enzymology
Pravastatin / pharmacology*
Pravastatin / therapeutic use

Substances

Anticholesteremic Agents
CD40 Ligand
C-Reactive Protein
Matrix Metalloproteinase 9
Pravastatin